GSK’s Viehbacher Charged To “Adapt” Sanofi-Aventis To New Realities
Executive Summary
The backdrop for the change in command at Sanofi-Aventis is a string of product development setbacks stretching back to Zimulti (rimonabant) in June 2007, and more recently including the antidepressant amibegron, the gastric cancer agent S-1, the refractory ovarian cancer agent aflibercept and saredutant for major depression
You may also be interested in...
Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity
Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity